V Square Quantitative Management LLC Has $1.98 Million Position in AbbVie Inc. (NYSE:ABBV)

V Square Quantitative Management LLC lifted its holdings in AbbVie Inc. (NYSE:ABBV) by 3.3% during the 4th quarter, HoldingsChannel reports. The fund owned 11,114 shares of the company’s stock after acquiring an additional 350 shares during the quarter. V Square Quantitative Management LLC’s holdings in AbbVie were worth $1,975,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of ABBV. AMF Tjanstepension AB acquired a new stake in shares of AbbVie during the 3rd quarter worth approximately $8,777,000. Creative Planning lifted its stake in AbbVie by 5.8% during the 3rd quarter. Creative Planning now owns 750,811 shares of the company’s stock valued at $147,086,000 after acquiring an additional 40,925 shares in the last quarter. Swedbank AB lifted its stake in AbbVie by 0.3% during the 3rd quarter. Swedbank AB now owns 2,147,126 shares of the company’s stock valued at $424,014,000 after acquiring an additional 6,810 shares in the last quarter. ERn Financial LLC bought a new stake in shares of AbbVie during the 3rd quarter worth $215,000. Finally, Kapitalo Investimentos Ltda bought a new stake in shares of AbbVie during the 3rd quarter worth $259,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Stock Up 0.3 %

NYSE ABBV opened at $193.54 on Friday. The stock’s 50-day moving average price is $178.24 and its 200-day moving average price is $185.91. The company has a quick ratio of 0.54, a current ratio of 0.65 and a debt-to-equity ratio of 9.64. AbbVie Inc. has a 52 week low of $153.58 and a 52 week high of $207.32. The company has a market capitalization of $342.00 billion, a P/E ratio of 80.64, a price-to-earnings-growth ratio of 1.53 and a beta of 0.58.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, January 31st. The company reported $2.16 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a return on equity of 257.91% and a net margin of 7.59%. During the same period in the prior year, the company posted $2.79 earnings per share. On average, equities research analysts predict that AbbVie Inc. will post 12.32 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on ABBV. Bank of America reaffirmed a “neutral” rating and set a $191.00 target price on shares of AbbVie in a report on Tuesday, December 10th. Morgan Stanley boosted their target price on AbbVie from $224.00 to $239.00 and gave the stock an “overweight” rating in a research report on Monday, February 3rd. Wolfe Research started coverage on AbbVie in a research report on Friday, November 15th. They issued an “outperform” rating and a $205.00 price objective for the company. BMO Capital Markets upped their target price on AbbVie from $208.00 to $215.00 and gave the company an “outperform” rating in a report on Monday, February 3rd. Finally, Piper Sandler Companies restated an “overweight” rating and set a $220.00 target price on shares of AbbVie in a report on Tuesday, December 17th. Five investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $208.35.

Insider Buying and Selling at AbbVie

In related news, SVP Kevin K. Buckbee sold 1,800 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $172.24, for a total transaction of $310,032.00. Following the completion of the sale, the senior vice president now directly owns 6,983 shares of the company’s stock, valued at approximately $1,202,751.92. This trade represents a 20.49 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.25% of the stock is currently owned by company insiders.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.